Loading...
Recent clinical findings on the role of kinase inhibitors in COVID-19 management
Malekinejad, Z ; Sharif University of Technology | 2022
162
Viewed
- Type of Document: Article
- DOI: 10.1016/j.lfs.2022.120809
- Publisher: Elsevier Inc , 2022
- Abstract:
- The highly pathogenic, novel coronavirus disease (COVID-19) outbreak has emerged as a once-in-a-century pandemic with poor consequences, urgently calling for new therapeutics, cures, and supportive interventions. It has already affected over 250 million people worldwide; thereby, there is a need for novel therapies to alleviate the related complications. There is a paradigm shift in developing drugs and clinical practices to combat COVID-19. Several clinical trials have been performed or are testing diverse pharmacological interventions to alleviate viral load and complications such as cytokine release storm (CRS). Kinase-inhibitors have appeared as potential antiviral agents for COVID-19 patients due to their efficacy against CRS. Combination of kinase inhibitors with other therapies can achieve more efficacy against COVID-19. Based on the pre-clinical trials, kinase inhibitors such as Janus kinase-signal transducer and activator of transcription (JAK/STAT) inhibitors, Brutton's tyrosin kinase (BTK) inhibitors, p38 mitogen-activated protein kinases (p38 MAPK) inhibitors, Glycogen synthase kinase 3 (GSK-3) inhibitors can be a promising strategy against COVID-19. Kinase inhibitors possess crucial pharmacological properties for a successful re-purposing in terms of dual anti-inflammatory and anti-viral effects. This review will address the current clinical evidence and the newest discovery regarding the application of kinase inhibitors in COVID-19. An outlook on ongoing clinical trials (clinicaltrials.gov) and unpublished data is also presented here. Besides, Kinase inhibitors' function on COVID-19-mediated CRS is discussed. © 2022 Elsevier Inc
- Keywords:
- BTK ; COVID-19 ; CRS ; GSK-3 ; JAK/STAT ; Kinase inhibitor ; p38 MAPK ; Signaling ; Antivirus agent ; Glycogen synthase kinase 3 ; Mitogen activated protein kinase p38 ; Cytokine release syndrome ; Drug therapy ; Human ; Pandemic ; Signal transduction ; Antiviral Agents ; COVID-19 ; Cytokine Release Syndrome ; Glycogen Synthase Kinase 3 ; Humans ; P38 Mitogen-Activated Protein Kinases ; Pandemics ; Signal Transduction
- Source: Life Sciences ; Volume 306 , 2022 ; 00243205 (ISSN)
- URL: https://www.sciencedirect.com/science/article/pii/S0024320522005094